Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MART-127-35 peptide-pulsed dendritic cells
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
MART-127-35 peptide-pulsed dendritic cells are an autologous cell therapy product created by pulsing patients' own dendritic cells in vitro with the MART-1(27-35) peptide, a melanoma antigen epitope. These peptide-pulsed dendritic cells are then administered to patients to stimulate a tumor-specific immune response, primarily activating MART-1-specific cytotoxic (CD8+) T cells, and sometimes helper (CD4+) T cells, against melanoma cells. The approach is a type of personalized cancer immunotherapy, leveraging dendritic cell antigen presentation to induce targeted anti-tumor immunity. Primary indications have been metastatic and advanced melanoma. The therapy is typically administered in the context of clinical trials and is not a commercial product.
- Other names
- MART-1 27-35 peptide-pulsed dendritic cellsMART1 27-35 peptide-pulsed dendritic cellsMART 1 27-35 peptide-pulsed dendritic cellsMART-1_27-35 peptide-pulsed dendritic cells
02
Targets
MART-1/HLA-A*02:01 (Melanoma-associated antigen (Melanoma antigen recognized by T cells 1, Melanocyte protein PMEL, Tyrosinase) peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on MART-127-35 peptide-pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MART-127-35 peptide-pulsed dendritic cells.